Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Amazon Explores AI Content Marketplace With Media Publishers 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
 and Lead Plaintiff Deadline: February 20, 2018 - EconoTimes)
Attorney Advertising-- NEW YORK, Jan. 08, 2018 -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Philip Morris International Inc. ("Philip Morris" or the "Company") (NYSE:PM) and certain of its officers, on behalf of shareholders who purchased Philip Morris securities between July 26, 2016 and December 20, 2017, both dates inclusive (“Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/pm.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The complaint alleges that Defendants made false and/or misleading statements and failed to disclose that: (1) there were irregularities in the clinical experiments that underpin Philip Morris’ application to the FDA for approval of its iQOS smoking device; and (2) consequently, defendants’ statements about Philip Morris’ business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/pm or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Philip Morris you have until February 20, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
